Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer

NCT04243499 is registered in ClinicalTrials.gov with ImCheck Therapeutics, an Ipsen company as lead sponsor.

NCT NCT04243499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04243499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
Lead sponsor
ImCheck Therapeutics, an Ipsen company
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 5, 2020
Completion date
October 15, 2027
Enrollment
293 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic/lymphoid cancer, solid tumor, adult